Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Mitoxantrone and Prednisone in Taxane-Refractory mHRPC
NCT00452387Phase 2Terminated
- Sponsor
- Accelerated Community Oncology Research Network
- Start
- May 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Accelerated Community Oncology Research Network. Primary endpoint: Median Time to Progression. Started May 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00452387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452387.